Biopharma organizations are exploring artificial intelligence across multiple use cases: patient identification, data analysis, regulatory submissions, and beyond. Along the way, they’re seeing both short- and long-term success; some changes are fast, and others are slow.
But as clinical trial leaders embrace the opportunities, they’re also contending with challenges—such as a criticism of algorithm bias and concerns around data security. With these problems jeopardizing new possibilities, experts recommend a strategic approach to AI and ML adoption that accounts for the implications of this tech now and in the future.
The following report unpacks what’s new, exploring perspectives surrounding AI and ML in clinical trials and experts’ predictions for the future. You’ll learn:
Thank you for your interest in the report. Click below to get your copy!Download Now
Enter the 6 digit code sent to your mobile number
Click on Resend the verification code again